Thus, significant attention is being focused on the AEGIS II trial, in which apoA-I in a proprietary lipid formulation used to simulate HDL particles (CSL112) is administered to subjects with ACS (acute coronary syndrome). Here, APOA1 is linked to acute coronary syndrome.